0HS8:LSE Caladrius Biosciences Inc.

USD 2.67 0.00 0
Icon

Caladrius Biosciences Inc. (0HS8:LSE) Stock Analysis and Price Targets

COMMON STOCK | | LSE
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.67

0.00 (0.00)%

N/A

400.00

N/A

N/A

Icon

0HS8:LSE

Caladrius Biosciences Inc. (USD)
COMMON STOCK | LSE
USD 2.67
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

N/A

N/A

USD 2.67

Caladrius Biosciences Inc. (0HS8:LSE) Stock Forecast

N/A

Based on the Caladrius Biosciences Inc. stock forecast from 0 analysts, the average analyst target price for Caladrius Biosciences Inc. is not available over the next 12 months. Caladrius Biosciences Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Caladrius Biosciences Inc. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Caladrius Biosciences Inc.’s stock price was USD 2.67. Caladrius Biosciences Inc.’s stock price has changed by +0.00% over the past week, -19.00% over the past month and -16.09% over the last year.

No recent analyst target price found for Caladrius Biosciences Inc.
No recent average analyst rating found for Caladrius Biosciences Inc.

Company Overview Caladrius Biosciences Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinica...Read More

https://www.lisata.com

110 Allen Road, Basking Ridge, NJ, United States, 07920

25

December

USD

UK

Adjusted Closing Price for Caladrius Biosciences Inc. (0HS8:LSE)

Loading...

Unadjusted Closing Price for Caladrius Biosciences Inc. (0HS8:LSE)

Loading...

Share Trading Volume for Caladrius Biosciences Inc. Shares

Loading...

Compare Performance of Caladrius Biosciences Inc. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 0HS8:LSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Caladrius Biosciences Inc. (Sector: )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
0R2V:LSE
Apple Inc. +2.75 (+1.61%) USD9,223,372,036.85B 30.58 N/A

ETFs Containing 0HS8

Symbol Name 0HS8's Weight Expense Ratio Price(Change) Market Cap
DDIV
First Trust RBA Quality I.. 2.78 % 0.60 % +0.18 (+0.55%) USD0.05B

Frequently Asked Questions About Caladrius Biosciences Inc. (0HS8:LSE) Stock

Stock Target Advisor's fundamental analysis for Caladrius Biosciences Inc.'s stock is Neutral.

Unfortunately we do not have enough data on 0HS8:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 0HS8:LSE's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on 0HS8:LSE's stock to indicate if its overvalued.

The last closing price of 0HS8:LSE's stock was USD 2.67.

Unfortunately we do not currently have any market capitalization data for 0HS8:LSE's stock.

Unfortunately we do not have enough analyst data on 0HS8:LSE's stock to indicate whether its price will go up or not.

Following are ETFs with the highest allocation to Caladrius Biosciences Inc.'s stock :

DDIV

As per our most recent records Caladrius Biosciences Inc. has 25 Employees.

Caladrius Biosciences Inc.'s registered address is 110 Allen Road, Basking Ridge, NJ, United States, 07920. You can get more information about it from Caladrius Biosciences Inc.'s website at https://www.lisata.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...